Last reviewed · How we verify
NCT06725693
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
trial testing 18F/68Ga-Exendin 4 in GLP1-R-related Disease in 500 participants. Currently enrolling.
1 November 2027
Quick facts
| Lead sponsor | Tianjin Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 February 2019 |
| Primary completion | 1 November 2027 |
| Estimated completion | 1 November 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- 18F/68Ga-Exendin 4
Conditions studied
- GLP1-R-related Disease — all drugs for GLP1-R-related Disease →
- Tumor — all drugs for Tumor →
- Insulinoma — all drugs for Insulinoma →
- Positron Emission Tomography — all drugs for Positron Emission Tomography →
Sponsor
Tianjin Medical University
Who can join
Adults 18 to 80, any sex, with GLP1-R-related Disease or Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.
Mena E, Lindenberg L, Herscovitch P, Sadowski SM, et al · · 2025 · cited 3× · PMID 40447542 · DOI 10.1053/j.semnuclmed.2025.05.001 -
Comparison of PET/CT using <sup>68</sup>Ga-NOTA-Exendin-4 with <sup>68</sup>Ga-DOTATATE, <sup>18</sup>F-FDG, and conventional imaging in the localization of insulinomas.
Yu H, Bao X, Gu Y, Pan M, et al · · 2025 · cited 1× · PMID 40259061 · DOI 10.1007/s00259-025-07288-x -
p53: from understanding its structure to advances in therapeutic targeting.
Wang W, Liu X, Liu H, Abolhassani H, et al · · 2026 · PMID 41942427 · DOI 10.1038/s41392-025-02549-5
Verify or expand the search:
- PubMed search for NCT06725693
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GLP1-R-related Disease
Currently open trials in the same condition.
- NCT07006142 — Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists · NA · recruiting
Other Tianjin Medical University trials
Trials by the same sponsor.
- NCT07393685 — Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD · not yet recruiting
- NCT07306598 — [18F]NIDF PET Imaging in Tau-related Diseases · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06949670 — Alpha-Synuclein PET/CT in Various α-Syn-Related Disease · recruiting
- NCT06628531 — ALI & Pulmonary HA Deposition After SAH · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06725693 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06725693.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing